On June 02, 2016 Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, reported that the United States Patent and Trademark Office issued the Company US Patent 9,351,997 (Press release, Intensity Therapeutics, JUN 2, 2016, View Source;.pdf [SID:1234512967]). Schedule your 30 min Free 1stOncology Demo! "Intensity’s DfuseRxSM platform technology has identified our lead drug, INT230-6. This novel product has shown great promise in regressing tumors and extending life in murine models of severe metastatic cancer via a combination of tumor cell death and immune system activation. Animals with large tumors achieve a complete response and become immunized against re-inoculation of the same cancer," said Intensity’s President and CEO, Lewis H Bender. "This issued US patent allows us to protect the market exclusivity of our unique and potent drug product. As we continue to prosecute additional patent applications in the US and countries around the world, the issuance of patent 9,351,997 increases our confidence that the Company’s unique cancer treatment technology can be secured."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
About INT230-6
INT230-6 is a novel, anti-cancer drug product able to disperse through tumors and diffuse into cancer cells. The product was identified from Intensity’s DfuseRxSM platform technology. Using preclinical in vivo models of severe cancer, INT230-6 treatment results in substantial improvement in overall survival compared to standard therapies. The product can completely clear large tumors in animal models. Complete responders have long-term, durable protection even after multiple re-inoculations of the cancer. INT230-6 administration has shown an increased recruitment of immune cells to the tumor micro-environment.